
Pooja Vir, PhD
I have my PhD degree in Biochemistry, Cell Biology and Immunology. My major research interests include studying the biology of host immune response in immune mediated disease conditions that include infectious, metabolic and inherited disorders. I have significant expertise in immunological topics and techniques, including mechanisms of immune tolerance, novel single-cell techniques, analytical and critical analyses. It is specifically targeted to measure human T cells immunological activity that can be interpreted for a better diagnosis or prevention of the disease.
My current research projects have focused on the problem of neutralizing anti-drug antibodies in hemophilia A, clinically termed “inhibitors” that inhibit normal blood coagulation induced by administered therapeutic Factor VIII protein. This work comprised the elucidation of physiological Factor VIII expression sites in human endothelial cells pertinent for the development of targeted gene therapy and immuno-profiling of human T cells to address immunogenicity of Factor VIII (and other therapeutic proteins) using confocal microscopy and ELISPOT assays. Previous research efforts culminated in the development of single cell Fluorescence in situ hybridization based flow cytometry (FISH-Flow) assay to identify Mycobacterium tuberculosis (Mtb) antigen-specific cytokine signature in peripheral blood cells to distinguish between Mtb latent infection, and uninfected individuals; and identification of memory T cell specific cytokine signature to differentiate between Mtb latently infected individuals and active Tuberculosis patients.
Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk. Vir P, Gunasekera D, Dorjbal B, McDaniel D, Agrawal A, Merricks EP, Ragni MV, Leissinger CA, Stering AI, Lieuw K, Nichols TC, Pratt KP.J Thromb Haemost. 2024 Dec;22(12):3415-3430. |
Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2.HLA-DR4.Rag1KO.IL-2RγcKO.NOD) for COVID-19. Brumeanu TD, Vir P, Karim AF, Kar S, Benetiene D, Lok M, Greenhouse J, Putmon-Taylor T, Kitajewski C, Chung KK, Pratt KP, Casares SA.Hum Vaccin Immunother. 2022 Nov 30;18(5):2048622. |
Prediction of IL4 inducing peptides. Dhanda SK, Gupta S, Vir P, Raghava GP.Clin Dev Immunol. 2013;2013:263952. doi: 10.1155/2013/263952. Epub 2013 Dec 30. |
Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role? Pratt KP, Gunasekera D, Vir P, Tan S, Pierce GF, Olsen C, Butenas S, Mann KG.Blood Adv. 2023 Sep 12;7(17):4983-4998. |
Hemophilia A subjects with an intron-22 gene inversion mutation show CD4+ T-effector responses to multiple epitopes in FVIII. Gunasekera D, Vir P, Karim AF, Ragni MV, Pratt KP.Front Immunol. 2023 Mar 1;14:1128641. doi: 10.3389/fimmu.2023.1128641. eCollection 2023.PMID: 36936969 |
Identification and characterization of novel protein-derived arginine-rich cell-penetrating peptides. Gautam A, Sharma M, Vir P, Chaudhary K, Kapoor P, Kumar R, Nath SK, Raghava GP.Eur J Pharm Biopharm. 2015 Jan;89:93-106. doi: 10.1016/j.ejpb.2014.11.020. Epub 2014 Nov 29. |
Designing of interferon-gamma inducing MHC class-II binders. Dhanda SK, Vir P, Raghava GP.Biol Direct. 2013 Dec 5;8:30. doi: 10.1186/1745-6150-8-30. |
A Web-Based Platform for Designing Vaccines against Existing and Emerging Strains of Mycobacterium tuberculosis. Dhanda SK, Vir P, Singla D, Gupta S, Kumar S, Raghava GP.PLoS One. 2016 Apr 20;11(4):e0153771. doi: 10.1371/journal.pone.0153771. eCollection 2016. |
Active Tuberculosis Is Characterized by Highly Differentiated Effector Memory Th1 Cells. Arrigucci R, Lakehal K, Vir P, Handler D, Davidow AL, Herrera R, Estrada-Guzmán JD, Bushkin Y, Tyagi S, Lardizabal AA, Gennaro ML.Front Immunol. 2018 Sep 19;9:2127. |
Interaction of alveolar epithelial cells with CFP21, a mycobacterial cutinase-like enzyme. Vir P, Gupta D, Agarwal R, Verma I.Mol Cell Biochem. 2014 Nov;396(1-2):187-99. |
Immunomodulation of alveolar epithelial cells by Mycobacterium tuberculosis phosphatidylinositol mannosides results in apoptosis. Vir P, Gupta D, Agarwal R, Verma I.APMIS. 2014 Apr;122(4):268-82. |
Seraph 100 Microbind Affinity Blood Filter Does Not Clear Antibiotics: An Analysis of Antibiotic Concentration Data from PURIFY-OBS. DeLuca JP, Selig DJ, Vir P, Vuong CV, Della-Volpe J, Rivera IM, Park C, Levi B, Pratt KP, Stewart IJ.Blood Purif. 2024;53(5):379-385. |
Single-Cell Cytokine Gene Expression in Peripheral Blood Cells Correlates with Latent Tuberculosis Status. Vir P, Arrigucci R, Lakehal K, Davidow AL, Pine R, Tyagi S, Bushkin Y, Lardizabal A, Gennaro ML.PLoS One. 2015 Dec 14;10(12):e0144904. doi: 10.1371/journal.pone.0144904. |
The Seraph 100® Microbind Affinity Blood Filter Does Not Alter Levels of Circulating or Mucosal Antibodies in Critical COVID-19 Patients. Conner TL, Vir P, Laing ED, Stewart IJ, Mitre E, Pratt KP.Antibodies (Basel). 2024 Aug 6;13(3):65. |
Tuberculosis State Is Associated with Expression of Toll-Like Receptor 2 in Sputum Macrophages. Lakehal K, Levine D, Kerr KF, Vir P, Bruiners N, Lardizabal A, Gennaro ML, Pine R.mSphere. 2017 Nov 1;2(6):e00475-17. doi: 10.1128/mSphere.00475-17. |
FISH-Flow, a protocol for the concurrent detection of mRNA and protein in single cells using fluorescence in situ hybridization and flow cytometry. Arrigucci R, Bushkin Y, Radford F, Lakehal K, Vir P, Pine R, Martin D, Sugarman J, Zhao Y, Yap GS, Lardizabal AA, Tyagi S, Gennaro ML.Nat Protoc. 2017 Jun;12(6):1245-1260. |
Area of Research
Institution Affiliations
HJF Scientist II, Department of Medicine, in support of Uniformed Services University